Impact of Targeted Therapy on Cancer-Related Cognitive Impairment URCC-24060
Study #URCC-24060Randomized study to characterize differences in subjective CRCI longitudically among receiving TKIs for CML or CLL.
Description
Cancer-related cognitive impairment (CRCI) is common and distressing among cancer survivors. Tyrosine kinase inhibitors (TKIs) are among the first, most prolific, and most successful classes of targeted therapy. TKIs are also rapidly expanding, with over 40 FDA-approved TKIs for cancer. Studying the impact of TKIs on CRCI will improve awareness of CRCI, identify modifiable mechanisms, and inform development of new interventions.
Sponsor: NCI